Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
aberrant, Addendum, AHD, alert, antecedent, ASC, ASCO, asthma, ASU, autoimmune, azacitidine, backup, baseline, calendar, category, Celgene, Cephalon, Chapter, chosen, Codification, Codificationandthe, codified, crystalline, CTEP, delisted, delisting, dismissed, disorder, doubling, downsizing, drawdown, durable, effectuated, Eighty, elucidated, Entremed, exemption, expiry, Exploratory, fallen, Femara, fifty, glaucoma, hand, Hospira, hypomethylating, idiopathic, impede, incidence, input, installment, Journal, Korea, Lazard, letrozole, Letter, margin, mortality, myeloproliferative, Needham, nongovernmental, ODAC, older, ORR, par, polycystic, post, potency, PR, prime, promulgated, pulmonary, Ras, ratio, rationale, regained, regular, renegotiated, repair, rest, revoked, rheumatoid, Rigel, ROTH, saving, simplify, SPA, Specimen, spectrum, Spiro, strictly, subgroup, suboptimal, superseded, thereunder, ThinkEquity, Title, topic, transformed, travel, twenty, unaffected, unissued, Vion, virtue, waiting, Wall, wild, write, Xeloda
Removed:
abnormal, acquirer, AG, announcement, antifungal, APB, appealed, appointed, assay, assembled, cancelled, clotrimazole, consummated, defer, earliest, enrich, excessive, expression, FIN, final, fluorescent, Fluorescience, forma, half, Harvard, hundred, identification, IgA, interfere, measuring, Millennium, negotiated, NuChem, omitted, parent, Penetratin, pro, recover, reinitiated, renal, repaid, repurchased, retrospective, Schering, School, spending, standalone, strongly, sublet
Filing tables
Filing exhibits
Related press release
CYCC similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements (Nos. 333-134945, 333-140034, 333-147997 and 333-143786) of Cyclacel Pharmaceuticals, Inc. and in the related Prospectuses of our reports dated March 29, 2010, with respect to the consolidated financial reporting of Cyclacel Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2009.
/s/ Ernst & Young LLP |
London, England
March 29, 2010
March 29, 2010